Allogene Therapeutics (ALLO) Other Operating Expenses (2019 - 2025)

Allogene Therapeutics (ALLO) has 4 years of Other Operating Expenses data on file, last reported at $2.4 million in Q2 2025.

• For the quarter ending Q2 2025, Other Operating Expenses fell 52.25% year-over-year to $2.4 million; the trailing twelve-month figure through Mar 2026 stood at $2.4 million (down 84.84% YoY), and the FY2025 full-year result was $2.4 million, down 84.84% from the prior year.
• Other Operating Expenses declined to $2.4 million in Q2 2025, from $10.7 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $13.2 million in Q4 2023 to a low of $2.4 million in Q2 2025.
• A 3-year average of $7.8 million and a median of $7.9 million in 2024 frame the typical range for Other Operating Expenses.
• Peak annual rise in Other Operating Expenses reached 52.25% in 2025, while the deepest fall reached 52.25% in 2025.
• Tracing ALLO's Other Operating Expenses over 3 years: stood at $13.2 million in 2023, then decreased by 19.0% to $10.7 million in 2024, then sank by 77.8% to $2.4 million in 2025.
• Business Quant data shows ALLO's Other Operating Expenses at $2.4 million in Q2 2025, $10.7 million in Q3 2024, and $5.0 million in Q2 2024.